Parkinsonism following neuroleptic exposure: A double-hit hypothesis?

Movement Disorders

Volumn 30, Issue 6, 2015, Pages 780-785

  Erro, Roberto ^a,b   Bhatia, Kailash P ^a   Tinazzi, Michele ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Anti pychotics; Drug induced parkinsonism; Neuroleptics; Parkinson's disease; Pathophysiology

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; DRUG EXPOSURE; GENETIC SUSCEPTIBILITY; HUMAN; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; GENETIC PREDISPOSITION; PARKINSON DISEASE; TIME;

ANTIPSYCHOTIC AGENTS; BRAIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PREVALENCE; RISK FACTORS; TIME FACTORS;

EID: 84929654369     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26209     Document Type: Article

References (54)

1. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-1083.
2. López-Sendón JL, Mena MA, de Yébenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012;29:105-118.
3. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-1220.
4. Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M . Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014;20:808-814.
5. Klawans HL Jr, Bergen D, Bruyn GW. Prolonged drug-induced Parkinsonism. Confin Neurol 1973;35:368-377.
6. Martí-Massó JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998;13:453-456.
7. Fahn S, Jankovic J, eds. Principles and Practice of Movement Disorders. Philadelphia, PA: Churchill Livingstone, 2007: 631 pp.
8. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol 1982;39:644-646.
9. Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging 2010;37:556-564.
10. Olivares Romero J, Ariona Padillo A. Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study. Neurologia 2013;28:276-282.
11. Tinazzi M, Ottaviani S, Isaias IU, et al. 123I.FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 2008;15;23:1825-1829.
12. Tinazzi M, Antonini A, Bovi T, et al. Clinical and 123I.FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009;256:910-915.
13. 123I.FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophr Res 2012;139:40-45.
14. Tinazzi M, Morgante F, Matinella A, et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Schizophr Res 2014;152:344-349.
15. Lee PH, Kim JS, Shin DH, Yoon SN, Huh K. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2006;77:372-374.
16. Lee PH, Yeo SH, Yong SW, Yun JK. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2007;78:1250-1252.
17. Kim JS, Oh YS, Kim YI, et al. Combined use of 123Imetaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug induced Parkinsonism (DIP): a 2-year follow-up study. Arch Gerontol Geriatr 2013;56:124-128.
18. Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012;79:1615-1621.
19. Yang SY, Kao Yang YH, Chong MY, Yang YH, Chang WH, Lai CS. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007;81:586-594.
20. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006;163:396-401.
21. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.
22. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-282.
23. Kennedy PF, Hershon HI, McGuire RJ. Extrapyramidal disorders after prolonged phenothiazine therapy. Br J Psychiatry 1971;118:509-518.
24. de la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011;69:803-810.
25. Shiroma PR, Geda YE, Mrazek DA. Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics 2010;11:1305-1330.
26. Kasten M, Brüggemann N, König IR, et al. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl) 2011;214:729-736.
27. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009;206:491-499.
28. Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2006;5:759-771.
29. Mena MA, Garcia de Yébenes MJ, Tabernero C, Casarejos MJ, Pardo B, Garcia de Yébenes J. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995;18:410-426.
30. Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli N Jr. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994;268:380-387.
31. Meredith GE, Switzer RC 3rd, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum. Brain Res 2004;995:14-22.
32. Fà M, Mereu G, Ghiglieri V, Meloni A, Salis P, Gessa GL. Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat. Synapse 2003;48:1-9.
33. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993;33:512-517.
34. Veitch K, Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol Pharmacol 1994;45:158-163.
35. Maurer I, Möller HJ. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 1997;174:255-259.
36. Park J, Chung S, An H, et al. Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons. Neuroscience 2012;209:64-73.
37. Iwahashi K, Anemo K, Nakamura K, Fukunishi I, Igarashi K. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism. Neuropsychobiology 2001;44:126-128.
38. Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Pharmacopsychiatry 2005;38:171-177.
39. Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 1999;55:599-604.
40. Eyles DW, McGrath JJ, Pond SM. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology 1996;125:214-219.
41. Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003;278:43628-43635.
42. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 2005;102:2174-2179.
43. Itier JM, Ibanez P, Mena MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003;12:2277-2291.
44. Serrano A, Menéndez J, Casarejos MJ, et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 2005;49:208-219.
45. Solano RM, Casarejos MJ, Menéndez-Cuervo J, Rodriguez-Navarro JA, García de Yébenes J, Mena MA. Glial dysfunction in parkin null mice: effects of aging. J Neurosci 2008;28:598-611.
46. Rodríguez-Navarro JA, Casarejos MJ, Menéndez J, et al. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 2007;103:98-114.
47. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
48. Choi DY, Liu M, Hunter RL, et al. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 2009;4:e5482. DOI: 10.1371/journal.pone.0005482.
49. Mencacci NE, Isaias IU, Reich MM, et al. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 2014;137:2480-2492.
50. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003;373:25-32.
51. Vaarmann A, Kovac S, Holmstrom KM, Gandhi S, Abramov AY. Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis 2013;4:e455.
52. Madeo G, Schirinzi T, Martella G, et al. PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. Mov Disord 2014;29:41-53.
53. Bartels AL, Leenders KL. Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with 11C.-PK11195 PET. Mov Disord 2007;22:1852-1856.
54. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168-175.